Standort: ---
Exemplare:
---
| Online-Ressource |
Verfasst von: | Strobel, Sophia [VerfasserIn]  |
| Machiraju, Devayani [VerfasserIn]  |
| Kälber, Katharina [VerfasserIn]  |
| Hassel, Jessica C. [VerfasserIn]  |
Titel: | Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment |
Verf.angabe: | Sophia B. Strobel, Devayani Machiraju, Katharina A. Kälber, Jessica C. Hassel |
E-Jahr: | 2022 |
Jahr: | 23 December 2021 |
Jahr des Originals: | 2021 |
Umfang: | 6 S. |
Fussnoten: | Gesehen am 06.06.2023 |
Titel Quelle: | Enthalten in: Cancer immunology immunotherapy |
Ort Quelle: | Berlin : Springer, 1976 |
Jahr Quelle: | 2022 |
Band/Heft Quelle: | 71(2022), 8, Seite 2051-2056 |
ISSN Quelle: | 1432-0851 |
Abstract: | To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we investigated the frequency of general side effects and immune-related AEs of COVID-19 vaccination. A triage survey was used to collect the following information for patients with metastatic skin cancer: vaccine type, date of receipt of each dose of vaccine, and self-reported side effects. Clinical data were retrieved from the patients’ medical records. Of 130 patients with metastatic skin cancer, 89 patients were on immunotherapy and received COVID-19 vaccination. Of these 89 patients (median age: 64 years; 57 [64%] men), 89% had melanoma, and 71% received ICI therapy with a PD-1 antibody. Eighty-eight percent received an mRNA-based COVID-19 vaccination. The median follow-up time was 125 days after the first vaccination, and 84 days after the second. The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%). Grade 3 irAEs were reported in eight patients, seven of whom were on nivolumab plus ipilimumab combination treatment. Of the 19 patients vaccinated within 72 h before/after ICI, five developed irAEs within 17 days (1-17 days). This small cohort study suggests that approved COVID-19 vaccinations are safe for use in cancer patients receiving ICIs. However, some precautions should be taken, especially regarding the timing of vaccination and ICI treatment. |
DOI: | doi:10.1007/s00262-021-03133-w |
URL: | kostenfrei: Volltext: https://doi.org/10.1007/s00262-021-03133-w |
| DOI: https://doi.org/10.1007/s00262-021-03133-w |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Adverse events |
| Cancer patients |
| COVID-19 vaccination |
| Immune-checkpoint inhibitors |
K10plus-PPN: | 1847534716 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment / Strobel, Sophia [VerfasserIn]; 23 December 2021 (Online-Ressource)
69082956